Application No.		No.	Applicant(s)	
Notice of Allowability	10/039,836		CRANE ET AL.	
	Examiner		Art Unit	
	Anna D. Kub.	-1:1 <i>c</i>	1620	
	Anne R. Kube	∍IIK	1638	
The MAILING DATE of this communication appears on the cover sheet with the correspondence address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.				
1. This communication is responsive to <u>amendments filed 2 June 2003</u> .				
2. The allowed claim(s) is/are 18-24, renumbered as claims 1-7.				
<ul> <li>3.  The drawings filed on are accepted by the Examiner.</li> <li>4.  Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).</li> </ul>				
a) ☐ All b) ☐ Some* c) ☐ None of the:				
1. Certified copies of the priority documents have been received.				
2. Certified copies of the priority documents have been received in Application No				
3. Copies of the certified copies of the priority documents have been received in this national stage application from the				
International Bureau (PCT Rule 17.2(a)).				
* Certified copies not received:  5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).				
(a) The translation of the foreign language provisional application has been received.				
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.				
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE				
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.				
8. CORRECTED DRAWINGS must be submitted.				
(a) 🔲 including changes required by the Notice of Draftsperson's Patent Drawing Review ( PTO-948) attached				
1) 🗌 hereto or 2) 🗍 to Paper No				
(b) including changes required by the proposed drawing correction filed, which has been approved by the Examiner.				
(c) 🔲 including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No				
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet.				
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.				
Attachment(s)				
<ul> <li>1 ☐ Notice of References Cited (PTO-892)</li> <li>3 ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)</li> <li>5 ☐ Information Disclosure Statements (PTO-1449), Paper No</li> <li>7 ☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material</li> </ul>	·	2☐ Notice of Informa 4☑ Interview Summa 6☑ Examiner's Amer 8☐ Examiner's State 9☐ Other .	ary (PTO-413), Paper adment/Comment	No

Application/Control Number: 10/039,836

Art Unit: 1638

## Examiner's Amendment

Page 2

1. An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Claire Moxon on 6 November 2003.

Claims 1-17 are cancelled without prejudice.

Claim 18. (Amended) An isolated nucleotide sequence [selected from the group consisting of:

- (a) a nucleotide sequence] comprising the sequence set forth in SEQ ID NO:3[;
- (b) a nucleotide sequence having at least 95% identity to SEQ ID NO:3, wherein said nucleotide sequence is capable of regulating transcription].

Claim 21. (amended) A plant having stably incorporated into its genome at least one DNA construct comprising a nucleotide sequence of interest operably linked to a promoter,

wherein said nucleotide sequence of interest is heterologous to said promoter and wherein said promoter [is selected from the group consisting of:

(a) a promoter sequence comprising] comprises the sequence set forth in SEQ ID NO:3[;

Application/Control Number: 10/039,836 Page 3

Art Unit: 1638

(b) a promoter sequence having at 95% identity to SEQ ID NO:3 wherein said promoter sequence regulates transcription of said nucleotide sequence of interest].

In claim 22, "having" was replaced with --comprising--.

2. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Anne R. Kubelik, whose telephone number is (703) 308-5059. The examiner can normally be reached Monday through Friday, 8:30 am - 5:00 pm. Sometime in January 2004, the examiner's phone number will change to (571) 272-0801.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Amy Nelson, can be reached at (703) 306-3218. The fax phone number for the organization where this application or proceeding is assigned is (703) 872-9306.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to Customer Service at (703) 308-0198.

Anne R. Kubelik, Ph.D. November 6, 2003

AMY J. NELSON, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

Any Nel